WO2003088748A8 - Use of heme oxygenase-1 and products of heme degradation - Google Patents
Use of heme oxygenase-1 and products of heme degradationInfo
- Publication number
- WO2003088748A8 WO2003088748A8 PCT/US2003/011411 US0311411W WO03088748A8 WO 2003088748 A8 WO2003088748 A8 WO 2003088748A8 US 0311411 W US0311411 W US 0311411W WO 03088748 A8 WO03088748 A8 WO 03088748A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heme
- products
- degradation
- oxygenase
- heme oxygenase
- Prior art date
Links
- 102000002737 Heme Oxygenase-1 Human genes 0.000 title abstract 2
- 108010018924 Heme Oxygenase-1 Proteins 0.000 title abstract 2
- 150000003278 haem Chemical class 0.000 title abstract 2
- 230000015556 catabolic process Effects 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 239000007857 degradation product Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/99—Miscellaneous (1.14.99)
- C12Y114/99003—Heme oxygenase (1.14.99.3)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03746978A EP1499186A4 (en) | 2002-04-15 | 2003-04-15 | Use of heme oxygenase-1 and products of heme degradation |
JP2003585506A JP2005522521A (en) | 2002-04-15 | 2003-04-15 | Use of heme oxygenase-1 and heme degradation products |
AU2003226366A AU2003226366A1 (en) | 2002-04-15 | 2003-04-15 | Use of heme oxygenase-1 and products of heme degradation |
CA002482260A CA2482260A1 (en) | 2002-04-15 | 2003-04-15 | Use of heme oxygenase-1 and products of heme degradation |
US10/511,612 US8097585B2 (en) | 2002-04-15 | 2003-04-15 | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
AU2009227862A AU2009227862A1 (en) | 2002-04-15 | 2009-10-19 | Use of heme oxygenase-1 and products of heme degradation |
US13/315,791 US20120195976A1 (en) | 2002-04-15 | 2011-12-09 | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37276202P | 2002-04-15 | 2002-04-15 | |
US60/372,762 | 2002-04-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/315,791 Continuation US20120195976A1 (en) | 2002-04-15 | 2011-12-09 | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003088748A1 WO2003088748A1 (en) | 2003-10-30 |
WO2003088748A8 true WO2003088748A8 (en) | 2004-01-29 |
Family
ID=29250903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/011411 WO2003088748A1 (en) | 2002-04-15 | 2003-04-15 | Use of heme oxygenase-1 and products of heme degradation |
Country Status (6)
Country | Link |
---|---|
US (2) | US8097585B2 (en) |
EP (1) | EP1499186A4 (en) |
JP (1) | JP2005522521A (en) |
AU (2) | AU2003226366A1 (en) |
CA (1) | CA2482260A1 (en) |
WO (1) | WO2003088748A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8128963B2 (en) * | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US7678390B2 (en) * | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
SK15942003A3 (en) * | 2001-06-21 | 2004-08-03 | Beth Israel Deaconess Medical Center, Inc. | Carbon monoxide improves outcomes in tissue and organ transplants apoptosis |
JP2005525848A (en) * | 2002-02-13 | 2005-09-02 | ベス イスラエル ディコネス メディカル センター | Treatment method of vascular disease |
AU2003216368B2 (en) * | 2002-04-15 | 2007-08-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating ileus |
US8097585B2 (en) | 2002-04-15 | 2012-01-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
AU2003223562B2 (en) * | 2002-04-15 | 2009-04-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating necrotizing enterocolitis |
US20040052866A1 (en) * | 2002-05-17 | 2004-03-18 | Otterbein Leo E. | Methods of treating hepatitis |
PL375161A1 (en) * | 2002-06-21 | 2005-11-28 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
US20040228930A1 (en) * | 2002-11-07 | 2004-11-18 | Billiar Timothy R. | Treatment for hemorrhagic shock |
US7504243B2 (en) * | 2004-03-19 | 2009-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the production of biliverdin |
WO2006054757A1 (en) * | 2004-11-16 | 2006-05-26 | Astellas Pharma Inc. | Caspase inhibitor |
WO2006132583A1 (en) * | 2005-06-07 | 2006-12-14 | Innate Pharmaceuticals Ab | Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection |
JPWO2007073005A1 (en) * | 2005-12-22 | 2009-06-04 | 学校法人慶應義塾 | Methyl group transfer regulator |
WO2008008513A2 (en) * | 2006-07-13 | 2008-01-17 | Beth Israel Deaconess Medical Center Inc. | Combination treatments |
WO2008113134A1 (en) * | 2007-03-20 | 2008-09-25 | Garvan Institute Of Medical Research | Method of transplantation of a kidney |
US20120177601A1 (en) * | 2009-07-02 | 2012-07-12 | The Usa As Represented By The Secretary Of The Department Of Veterans Affairs | Treatment of hepatitis c virus infections |
US8455222B2 (en) | 2009-11-04 | 2013-06-04 | Utah State University | Biliverdin from a non-animal source |
WO2014043647A1 (en) | 2012-09-14 | 2014-03-20 | Utah State University | Therapeutic compositions and associated methods |
US20140112882A1 (en) * | 2012-10-08 | 2014-04-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods to treat pancreatic inflammation and associated lung injury through regulation of pancreatic interleukin-22 expression |
EP2868348A1 (en) * | 2013-11-04 | 2015-05-06 | Universität Zürich | CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair |
EP3976636A1 (en) * | 2019-05-28 | 2022-04-06 | PreviPharma Consulting GmbH | Method for preparing iron-depleted ferritin and use thereof |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053590A (en) | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
JPS5381611A (en) | 1976-12-28 | 1978-07-19 | Kimihiko Okazaki | Hepatic medicine |
US4264739A (en) | 1979-01-05 | 1981-04-28 | Merck & Co., Inc. | Sparger for cell culture system |
JPS5679957A (en) | 1979-12-05 | 1981-06-30 | Sogo Seibutsu Igaku Kenkyusho:Kk | Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this |
US5240912A (en) | 1983-05-09 | 1993-08-31 | Todaro George J | Transforming growth factor (TGF) peptides |
US4979939A (en) | 1984-05-14 | 1990-12-25 | Surgical Systems & Instruments, Inc. | Atherectomy system with a guide wire |
US5084380A (en) | 1985-01-29 | 1992-01-28 | Applied Biotechnology | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
US5449665A (en) | 1985-09-24 | 1995-09-12 | Item Development Aktiebolag | Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty |
DE3739650C1 (en) | 1987-11-23 | 1989-05-24 | Immuno Ag | Fermenter for growing cell cultures |
US5180366A (en) | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5792325A (en) | 1990-11-15 | 1998-08-11 | Richardson, Jr.; William H. | Electric arc material processing system |
US5293875A (en) | 1992-06-16 | 1994-03-15 | Natus Medical Incorporated | In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods |
BR9405798A (en) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Methods for in vivo release of biological material and useful compositions thereof |
WO1994022482A1 (en) | 1993-03-26 | 1994-10-13 | Biorelease Technologies, Inc. | Compositions including heme-containing proteins and methods relating thereto |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5763431A (en) | 1993-08-20 | 1998-06-09 | Jackson; Meyer B. | Method for regulating neuropeptide hormone secretion |
DE4421433C1 (en) | 1994-06-18 | 1995-06-08 | Lohmann Therapie Syst Lts | Transdermal therapeutic system for treatment of, e.g., hypertension |
US5476764A (en) | 1994-09-16 | 1995-12-19 | The Regents Of The University Of California | Method using CO for extending the useful shelf-life of refrigerated red blood cells |
CA2132690A1 (en) | 1994-09-22 | 1996-03-23 | Dean Willis | Control and modulation of inflammatory response in humans in need of such control and modulation |
US6066333A (en) | 1994-09-22 | 2000-05-23 | William Harvey Research Limited | Pharmaceutical control of inflammation |
US5588960A (en) | 1994-12-01 | 1996-12-31 | Vidamed, Inc. | Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence |
US5664563A (en) | 1994-12-09 | 1997-09-09 | Cardiopulmonary Corporation | Pneumatic system |
US5914316A (en) | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
US5712293A (en) | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
FR2735382B1 (en) | 1995-06-15 | 1997-07-25 | Air Liquide | CARBON MONOXIDE PRODUCTION PLANT INCORPORATING A CRYOGENIC SEPARATION UNIT |
US5731326A (en) | 1995-06-30 | 1998-03-24 | Zymogenetics, Inc. | PDGF antagonists II |
DE19535781C2 (en) | 1995-09-26 | 1999-11-11 | Fraunhofer Ges Forschung | Device for active flow support of body fluids |
JP2000510448A (en) | 1996-04-05 | 2000-08-15 | ザ ジェネラル ホスピタル コーポレーション | Treatment of hemoglobinopathies |
US6069132A (en) | 1996-08-14 | 2000-05-30 | Revanker; Ganapathi R. | Phosphazole compounds |
JP2001500121A (en) | 1996-08-23 | 2001-01-09 | アルゴス ファーマシューティカル コーポレーション | Anticonvulsants comprising a composition for treating neuropathic pain |
PT921807E (en) | 1996-08-27 | 2004-04-30 | Messer Griesheim Gmbh | MEDICINES CONTAINING HYDROGEN |
US5756492A (en) * | 1996-09-09 | 1998-05-26 | Sangstat Medical Corporation | Graft survival prolongation with porphyrins |
US6315995B1 (en) | 1996-09-27 | 2001-11-13 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US6316403B1 (en) | 1996-09-27 | 2001-11-13 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US8128963B2 (en) | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
DK0951292T3 (en) | 1996-09-27 | 2007-08-13 | Univ Columbia | Treatment of an ischemic disorder and improvement of stroke outcome |
US6436365B2 (en) | 1997-09-23 | 2002-08-20 | Schering Aktiengesellschaft | Process for therapeutic treatment of proliferative diseases |
US6251418B1 (en) | 1997-12-18 | 2001-06-26 | C.R. Bard, Inc. | Systems and methods for local delivery of an agent |
CN100390163C (en) | 1998-03-16 | 2008-05-28 | 赛尔金有限公司 | 2-(2,6-dioxopiperidin-3-yl)-isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
US6450989B2 (en) | 1998-04-27 | 2002-09-17 | Artemis Medical, Inc. | Dilating and support apparatus with disease inhibitors and methods for use |
US6203991B1 (en) | 1998-08-21 | 2001-03-20 | The Regents Of The University Of Michigan | Inhibition of smooth muscle cell migration by heme oxygenase I |
AU2366900A (en) | 1998-12-17 | 2000-07-03 | Sangstat Medical Corporation | Methods for enhancing graft survival by modulating heme oxygenase activity |
US20050250688A1 (en) | 1999-04-01 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
WO2000061166A1 (en) * | 1999-04-14 | 2000-10-19 | Breonics, Inc. | System for exsanguinous metabolic support of an organ or tissue |
US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
US6508784B1 (en) | 2000-05-19 | 2003-01-21 | Yan-Ho Shu | Balloon catheter having adjustable centering capabilities and methods thereof |
FR2812197B1 (en) | 2000-07-27 | 2003-01-03 | Air Liquide Sante Int | USE OF CO IN THE TREATMENT OF INFLAMMATION OF THE UPPER AIRWAYS OR BRONCHIA |
US6902881B2 (en) | 2000-10-13 | 2005-06-07 | President And Fellows Of Harvard College | Compounds and methods for regulating cell differentiation |
FR2816212A1 (en) | 2000-11-03 | 2002-05-10 | Air Liquide Sante Int | Use of carbon monoxide to treat or prevent cardiovascular inflammation e.g. ischemia, reperfusion, stenosis, restenosis, and platelet aggregation |
WO2002080859A2 (en) | 2001-03-20 | 2002-10-17 | Glaxo Group Limited | Inhalation drug combinations |
US20030068387A1 (en) | 2001-03-30 | 2003-04-10 | Roland Buelow | Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
GB0111872D0 (en) | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
US7122027B2 (en) | 2001-05-25 | 2006-10-17 | Medtronic, Inc. | Implantable medical device with controllable gaseous agent release system |
SK15942003A3 (en) * | 2001-06-21 | 2004-08-03 | Beth Israel Deaconess Medical Center, Inc. | Carbon monoxide improves outcomes in tissue and organ transplants apoptosis |
EP2042181A1 (en) | 2002-02-04 | 2009-04-01 | ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. | Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
JP2005525848A (en) | 2002-02-13 | 2005-09-02 | ベス イスラエル ディコネス メディカル センター | Treatment method of vascular disease |
AU2003216368B2 (en) | 2002-04-15 | 2007-08-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating ileus |
AU2003223562B2 (en) | 2002-04-15 | 2009-04-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating necrotizing enterocolitis |
US8097585B2 (en) | 2002-04-15 | 2012-01-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
US20040052866A1 (en) | 2002-05-17 | 2004-03-18 | Otterbein Leo E. | Methods of treating hepatitis |
CA2487413A1 (en) | 2002-06-05 | 2003-12-18 | Yale University | Methods of treating angiogenesis, tumor growth, and metastasis |
PL375161A1 (en) | 2002-06-21 | 2005-11-28 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
DE10230165A1 (en) | 2002-07-04 | 2004-01-15 | Ino Therapeutics Gmbh | Method and device for the administration of carbon monoxide |
US20040228930A1 (en) | 2002-11-07 | 2004-11-18 | Billiar Timothy R. | Treatment for hemorrhagic shock |
US7504243B2 (en) * | 2004-03-19 | 2009-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the production of biliverdin |
-
2003
- 2003-04-15 US US10/511,612 patent/US8097585B2/en not_active Expired - Fee Related
- 2003-04-15 EP EP03746978A patent/EP1499186A4/en not_active Withdrawn
- 2003-04-15 JP JP2003585506A patent/JP2005522521A/en active Pending
- 2003-04-15 CA CA002482260A patent/CA2482260A1/en not_active Abandoned
- 2003-04-15 WO PCT/US2003/011411 patent/WO2003088748A1/en active Application Filing
- 2003-04-15 AU AU2003226366A patent/AU2003226366A1/en not_active Abandoned
-
2009
- 2009-10-19 AU AU2009227862A patent/AU2009227862A1/en not_active Abandoned
-
2011
- 2011-12-09 US US13/315,791 patent/US20120195976A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8097585B2 (en) | 2012-01-17 |
EP1499186A1 (en) | 2005-01-26 |
US20120195976A1 (en) | 2012-08-02 |
JP2005522521A (en) | 2005-07-28 |
AU2003226366A1 (en) | 2003-11-03 |
WO2003088748A1 (en) | 2003-10-30 |
CA2482260A1 (en) | 2003-10-30 |
EP1499186A4 (en) | 2009-10-28 |
US20060003922A1 (en) | 2006-01-05 |
AU2009227862A1 (en) | 2009-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003088748A8 (en) | Use of heme oxygenase-1 and products of heme degradation | |
WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
AU2003286567A1 (en) | Methods for the treatment of skin disorders | |
AU2003289888A1 (en) | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | |
AU2003300791A1 (en) | Combination therapy for the treatment of pain | |
AU2002361811A1 (en) | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | |
NO20035025D0 (en) | Use of osteopontin for treatment and / or prevention of neurological disorders | |
AU2003228819A1 (en) | Combinations for the treatment of inflammatory skin disorders | |
ZA200501288B (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma. | |
AU2002350254A1 (en) | Novel carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use | |
AU2003291480A1 (en) | Composition for the prevention and treatment of inflammation of the ear | |
AU2003258145A1 (en) | Substituted phenylindoles for the treatment of hiv | |
WO2005013911A3 (en) | Protective and therapeutic uses for tocotrienols | |
AU2003285281A1 (en) | Topical application of curcumin for the treatment of peripheral neuropathy | |
AU2003251875A1 (en) | Combination therapy for the treatment of neoplasms | |
WO2002060483A3 (en) | Perylenequinones for use as photosensitizers and sonosensitizers | |
AU2003278559A1 (en) | Herbal medicine containing cyclodextrins for the treatment of ear disorders | |
EG24959A (en) | Indoles useful in the treatment of androgenreceptor related diseases. | |
HUP0202638A2 (en) | Use of fermented wheat-germ extract for preparation of antiphlogistic compositions | |
AU2003289652A1 (en) | The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion | |
AU2003220026A1 (en) | Methods and compositions for the treatment of ischemia | |
AU2003266965A1 (en) | Use of carboxamides for the treatment of tinnitus | |
EP1539100A4 (en) | Composition and methods for the treatment of skin disorders | |
AU2003237460A1 (en) | Combination treatments for purinoceptor-related disorders | |
WO2004112690A3 (en) | 2-aminobenzoyl derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 44/2003 UNDER (81) ADD "VC" |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2482260 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003585506 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003226366 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003746978 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003746978 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006003922 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10511612 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10511612 Country of ref document: US |